申请人:Endosome Therapeutics, Inc.
公开号:US11324832B2
公开(公告)日:2022-05-10
The present invention relates to tripartite compounds comprising a modulator moiety for endosomal G protein-coupled receptors like neurokinin-1 receptor, a linker and a lipid anchor suitable for anchoring the tripartite compound into a plasma membrane. The present invention also relates to a prodrug and a pharmaceutical composition comprising the tripartite compound and the use of the tripartite compound for the treatment of a disease or disorder mediated by endosomal G protein-coupled receptors signalling like NK1R signalling.
本发明涉及三方化合物,其包含神经激肽-1 受体等内泌体 G 蛋白偶联受体的调节剂分子、连接体和适于将三方化合物锚定到质膜上的脂质锚。本发明还涉及包含三方化合物的原药和药物组合物,以及三方化合物用于治疗由内体G蛋白偶联受体信号(如NK1R信号)介导的疾病或紊乱。